Literature DB >> 17114164

Purposes of AAC device use for persons with ALS as reported by caregivers.

Melanie Fried-Oken1, Lynn Fox, Marie T Rau, Jill Tullman, Glory Baker, Mary Hindal, Nancy Wile, Jau-Shin Lou.   

Abstract

Thirty-four informal caregivers who support 26 persons with ALS reported on AAC technology use. Each caregiver completed the Communication Device Use Checklist, a survey tool developed for this study based on Light's (1988) classification of the purposes of social interaction (Augmentative and Alternative Communication, 4, 66-82). The checklist includes 17 purposes of communication and asks participants to judge importance, mode, and frequency of use for each purpose. Results show that the three communication purposes used most frequently and valued as important by caregivers involve regulating the behavior of others for basic needs and wants (getting needs met; giving instructions or directions to others; and clarifying needs). Consistent reports of use and frequency for the purposes of staying connected (social closeness) and discussing important issues (information transfer) indicate that AAC technology can assist the dyad in maintaining previous relationships. The face-to-face spontaneous conversation mode is used most frequently, despite the slow rate of production, the lack of permanence, and the demands on conversational partners during message generation. Clinical and research implications are discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17114164     DOI: 10.1080/07434610600650276

Source DB:  PubMed          Journal:  Augment Altern Commun        ISSN: 0743-4618            Impact factor:   2.214


  10 in total

1.  What's on Your Mind? Conversation Topics Chosen by People With Degenerative Cognitive-Linguistic Disorders for Communication Boards.

Authors:  Melanie Fried-Oken; Darlene Daniels; Olivia Ettinger; Aimee Mooney; Glory Noethe; Charity Rowland
Journal:  Am J Speech Lang Pathol       Date:  2015-05       Impact factor: 2.408

2.  Access interface strategies.

Authors:  Susan Fager; David R Beukelman; Melanie Fried-Oken; Tom Jakobs; John Baker
Journal:  Assist Technol       Date:  2011

Review 3.  Supportive and symptomatic management of amyotrophic lateral sclerosis.

Authors:  Esther V Hobson; Christopher J McDermott
Journal:  Nat Rev Neurol       Date:  2016-08-12       Impact factor: 42.937

4.  Communication Support for People with ALS.

Authors:  David Beukelman; Susan Fager; Amy Nordness
Journal:  Neurol Res Int       Date:  2011-04-14

5.  Communications Technology and Motor Neuron Disease: An Australian Survey of People With Motor Neuron Disease.

Authors:  Lynette Mackenzie; Prarthna Bhuta; Kim Rusten; Janet Devine; Anna Love; Penny Waterson
Journal:  JMIR Rehabil Assist Technol       Date:  2016-01-25

6.  Comparison of Four Control Methods for a Five-Choice Assistive Technology.

Authors:  Sebastian Halder; Kouji Takano; Kenji Kansaku
Journal:  Front Hum Neurosci       Date:  2018-06-06       Impact factor: 3.169

7.  Assistive Technologies for Communication Empower Patients With ALS to Generate and Self-Report Health Data.

Authors:  Ana Londral
Journal:  Front Neurol       Date:  2022-04-26       Impact factor: 4.086

8.  Comparison of eye tracking, electrooculography and an auditory brain-computer interface for binary communication: a case study with a participant in the locked-in state.

Authors:  Ivo Käthner; Andrea Kübler; Sebastian Halder
Journal:  J Neuroeng Rehabil       Date:  2015-09-04       Impact factor: 4.262

Review 9.  Communication Matters-Pitfalls and Promise of Hightech Communication Devices in Palliative Care of Severely Physically Disabled Patients With Amyotrophic Lateral Sclerosis.

Authors:  Katharina Linse; Elisa Aust; Markus Joos; Andreas Hermann
Journal:  Front Neurol       Date:  2018-07-27       Impact factor: 4.003

10.  Communication Support Needs in Adults with Intellectual Disabilities and Its Relation to Quality of Life.

Authors:  Juan Carlos García; Emiliano Díez; Dominika Z Wojcik; Mónica Santamaría
Journal:  Int J Environ Res Public Health       Date:  2020-10-09       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.